Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables: 2009-2024

Historic Receivables for Ani Pharmaceuticals (ANIP) over the last 14 years, with Dec 2024 value amounting to $221.7 million.

  • Ani Pharmaceuticals' Receivables rose 28.65% to $252.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.3 million, marking a year-over-year increase of 32.05%. This contributed to the annual value of $221.7 million for FY2024, which is 36.80% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Receivables stood at $221.7 million for FY2024, which was up 36.80% from $162.1 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Receivables peaked at $221.7 million during FY2024, and registered a low of $95.8 million during FY2020.
  • Moreover, its 3-year median value for Receivables was $170.4 million (2022), whereas its average is $184.7 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Receivables decreased by 4.90% in 2023 and then spiked by 36.80% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Receivables (Yearly) stood at $95.8 million in 2020, then skyrocketed by 34.17% to $128.5 million in 2021, then surged by 32.61% to $170.4 million in 2022, then decreased by 4.90% to $162.1 million in 2023, then spiked by 36.80% to $221.7 million in 2024.